Zymeworks Inc. announced Dr. Jeffrey Smith has been promoted to Executive Vice President and Chief Medical Officer, where he will play a key role in leading the clinical development of early-stage programs and overseeing integrated global early-stage development group. Dr. John Fann has been promoted to Senior Vice President, Process Sciences, where he will continue to play a key role in supporting the advancement of new product candidates from preclinical studies into clinical trials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.26 USD | +1.85% | -6.67% | -20.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.50% | 583M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-8.21% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc Announces Additional Leadership Appointments